While the relationship between BCL-2 expression and CHOP therapy resistance is well established [13,14], it has remained unclear how CHOP treatment affects anti-apoptotic proteins in DLBCL. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.